SCHEMBL9498914

SCHEMBL9498914

N[C@H](Cc1ccccc1)[C@H](O)C(=O)NC1(C(=O)O)CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LAP3 P28838 5/20 0.54
ANPEP P15144 1/20 0.54
RNPEP Q9H4A4 1/20 0.54
DNPEP Q9ULA0 1/20 0.54
LTA4H P09960 2/20 0.43
SLC15A1 P46059 2/20 0.42
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
CXCR2 P25025 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ALPI P09923 1/20 0.40
PKM P14618 1/20 0.40
PTGS1 P23219 1/20 0.40
XIAP P98170 1/20 0.40
SLC7A5 Q01650 1/20 0.40
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
FABP4 P15090 3/20 0.39
FABP5 Q01469 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9498619 0.85 LAP3 (0.42) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL9500536 0.85 LAP3 (0.42) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL9500894 0.85 LAP3 (0.42) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL9500855 0.84 LAP3 (0.41) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL9500612 0.82 LAP3 (0.42) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL8012404 0.80 LAP3 (0.58) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL9500847 0.79 LAP3 (0.44) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL7439118 0.77 MME (0.55) ALDH1A1
SCHEMBL28799524 0.77 LAP3 (0.64) LAP3ANPEPRNPEPDNPEPLTA4H
SCHEMBL28799521 0.77 LAP3 (0.64) LAP3ANPEPRNPEPDNPEPLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702005-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE Metabolon Inc. (US) 2026-03-04 EP disclosed
US-20250120927-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE METABOLON INC. 2025-04-17 US disclosed
WO-2024227056-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE METABOLON INC. (US) 2024-10-31 WO disclosed
EP-0333000-B1 PEPTIDES WITH INHIBITORY ACTIVITY OF ENZYMATIC SYSTEMS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZAMBON GROUP S.p.A. (IT) 1993-05-19 EP disclosed
US-5145872-A PEPTIDES WITH PHARMACEUTICAL ACTIVITY ZAMBON GROUP, S.P.A. (IT) 1992-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120927-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE CNDP2, DPP7, DPEP1 LAP3 131/4885ANPEP 54/4885RNPEP 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.